Program Book - Confex

Dore, Robin K., MD
Osteoporosis and Metabolic Bone Disease:
Clinical Aspects and Pathogenesis
Disclosure: Amgen, Takeda, UCB, Roche,
Sanofe-Aventis, Eli Lilly, Bristol-Meyers, Squibb,
2; Amgen, Novartis, Takeda, Pfizer, Abbott, 5;
Pfizer, UCB, Abbott, Takeda, Novartis, Eli Lilly,
Warner-Chilcott, 8
Dougados, Maxime, MD
Spondylarthropathies and Psoriatic Arthritis -
Clinical Aspects and Treatment III
Disclosure: Abbott Laboratories, 5; BMS, 5;
Merck Pharmaceuticals, 5; Pfizer Inc, 5; UCB, 5
Elewaut, Dirk, MD
Spondylarthropathies and Psoriatic Arthritis -
Clinical Aspects and Treatment I
Disclosure: Nothing to Disclose
Emery, Paul, MD, MA
Rheumatoid Arthritis Treatment - Small
Molecules, Biologics, Therapy: Existing
Disease-modifying Antirheumatic Drugs and
Corticosteroids
Disclosure: Nothing to Disclose
Espinoza, Luis R., MD
Spondylarthropathies and Psoriatic Arthritis -
Clinical Aspects and Treatment
Disclosure: Nothing to Disclose
E
F
Finnegan, Alison, PhD
Cytokines, Mediators, and Gene Regulation I
Disclosure: Nothing to Disclose
Fitzcharles, Mary-Ann, MD, MBChB
Fibromyalgia and Soft Tissue Disorders II
Disclosure: Lilly, Janssen, 5; Pfizer Inc, Valeant,
Lilly, Purdue, Janssen, 8
Flynn, John A., MD, MBA, MEd
Education: Medical Education
Disclosure: Nothing to Disclose
Frech, Tracy M., MD
Systemic Sclerosis Fibrosing Syndromes and
Raynaud’s - Clinical Aspects and Therapeutics II
Disclosure: Nothing to Disclose
Furst, Daniel E., MD
Rheumatoid Arthritis Treatment - Small
Molecules, Biologics, Therapy: Existing
Disease-modifying Antirheumatic Drugs and
Corticosteroids
Disclosure: Abbott, Actelion, Amgen, BMS,
BiogenIdec, Centocor, Gilead, GSK, NIH,
Novartis, Pfizer, Roche/Genentech, UCB, 5;
Abbott, Actelion, Amgen, BMS, Gilead, GSK,
NIH, Novartis, Pfizer, Roche/Genentech, UCB, 2;
Abbott, Actelion, UCB, 8; Corrona, 3
Gelber, Allan C., MD
ACR/ARHP Combined Rehabilitation Abstract
Session
Disclosure: Nothing to Disclose
G
Genant, Harry K., MD
Imaging of Rheumatic Disease II: X-ray,
Computed Tomography and Magnetic
Resonance Imaging
Disclosure: SAB for Amgern, BMS, Roche, Lilly,
Genentech, Servier, Pfizer and Synarc, 5
Gensler, Lianne S., MD
ARHP Clinical Practice/Patient Care I
Disclosure: Nothing to Disclose
Spondylarthropathies and Psoriatic Arthritis -
Clinical Aspects and Treatment IV
Disclosure: Nothing to Disclose
Gerlag, Danielle M., MD
Rheumatoid Arthritis - Human Etiology and
Pathogenesis I: Pathogenesis of the Earliest
Stages of Rheumatoid Arthritis
Disclosure: Nothing to Disclose
Giles, Jon T., MD, MPH
Rheumatoid Arthritis Clinical Aspects:
Cardiovascular Disease
Disclosure: Genentech and Biogen IDEC Inc, 5
Rheumatoid Arthritis Clinical Aspects: Predictors
of Outcome
Disclosure: Genentech and Biogen IDEC Inc, 5
Glant, Tibor T., MD, PhD
Rheumatoid Arthritis - Animal Models II
Disclosure: Nothing to Disclose
Goldenberg, Don L., MD
Fibromyalgia and Soft Tissue Disorders I
Disclosure: Pfizer Inc, Lilly, Forest, 5
Goldring, Mary, PhD
Biology and Pathology of Bone and Joint:
Molecular Targets For an Effective Therapy
Disclosure: Abbott Laboratories, 2, 5; Biomet
Biologics, 5; F. Hoffmann-La Roche, Ltd, 5; Fidia
Farmaceutici S.p.A., 5; Merck-Serono S.A,, 2
Gordon, Jessica K., MD
Systemic Sclerosis Fibrosing Syndromes and
Raynaud’s - Clinical Aspects and Therapeutics I
Disclosure: Nothing to Disclose
Greco, Carol M., PhD
ARHP Psychology/Social Sciences
Disclosure: National Institutes of Health, 2
Hajj-Ali, Rula, MD
Vasculitis I
Disclosure: Nothing to Disclose
Hanly, John G., MD
Systemic Lupus Erythematosus - Clinical
Aspects: Cardiac Disease/Organ Damage
Disclosure: Nothing to Disclose
Hansen, Karen E., MD, MS
Osteoporosis and Metabolic Bone Disease:
Clinical Aspects and Pathogenesis
Disclosure: NIH, 2
Haroon, Nigil, MD, MBBS
Spondylarthropathies and Psoriatic Arthritis –
Pathogenesis, Etiology
Disclosure: Nothing to Disclose
Helmick, Charles G., MD
ARHP Epidemiology and Public Health I
Disclosure: Nothing to Disclose
H
Herrick, Ariane
Systemic Sclerosis Fibrosing Syndromes and
Raynaud’s - Clinical Aspects and Therapeutics III
Disclosure: Actelion Pharmaceuticals US, 5, 8;
Orion, 9; Pfizer Inc, 5, 8; United Therapeutics, 9
Hillstrom, Howard J., PhD
ACR/ARHP Combined Epidemiology Abstract
Session
Disclosure: Stride Rite, 2
Hochberg, Marc, MD, MPH
ARHP Epidemiology and Public Health II
Disclosure: Abbott Laboratories, Amgen, Astra-
Zeneca Pharmaceuticals, Bioiberica S.A., Bristol
Myers Squibb, Covidien, Eli Lilly, Genentech/
Roche, Iroko Pharmaceuticals, Merck, EMD
Serono, NiCox S.A., Novartis Pharma AG, Pfizer,
Pozen, Smith and Nephew, Stryker LLC,, 5;
Theralogix LLC, 1; U.S. Bone and Joint Initiative,
6
Holoshitz, Joseph, MD
T-cell Biology and Targets in Autoimmune
Disease: Lymphocyte Biology and Targets in
Autoimmune Disease
Disclosure: Nothing to Disclose
I
Illei, Gabor G., MD
Sjögren’s Syndrome
Disclosure: Nothing to Disclose
Ilowite, Norman T., MD
Pediatric Rheumatology - Clinical and
Therapeutic Aspects: Treatment
Disclosure: Abbott Immunology
Pharmaceuticals, 8; Centocor, Inc, 5; Genentech
and Biogen IDEC Inc, 8; Novartis Pharmaceutical
Corporation, 5; Regeneron, 2
Imundo, Lisa F., MD
Pediatric Rheumatology - Clinical and
Therapeutic Aspects: Clinical Characteristics
Disclosure: Nothing to Disclose
Inman, Robert D., MD
Infection-Related Rheumatic Disease
Disclosure: Nothing to Disclose
Spondylarthropathies and Psoriatic Arthritis -
Clinical Aspects and Treatment I
Disclosure: Nothing to Disclose
Isaacs, John, PhD
Rheumatoid Arthritis Clinical Aspects: Predictors
of Outcome
Disclosure: Nothing to Disclose
J
Jacobsson, Lennart T.H., MD, PhD
Rheumatoid Arthritis Clinical Aspects: Risk of
Cardiovascular Disease
Disclosure: Nothing to Disclose
James, Judith A., MD, PhD
Systemic Lupus Erythematosus - Human Etiology
and Pathogenesis I
Disclosure: Nothing to Disclose
Jolly, Meenakshi, MD, MS
Epidemiology and Health Services Research VI:
Lupus/Vasculitis
Disclosure: Nothing to Disclose
2011 Program Book 397
Abstract Moderator disclosure